Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study

Author:

Eworuke EfeORCID,Shinde Mayura,Hou Laura,Paterson Michael J,Jensen Peter Bjødstrup,Maro Judith C,Rai Ashish,Scarnecchia DanielORCID,Pennap Dinci,Woronow Daniel,Ghosh Rebecca E,Welburn StephenORCID,Pottegard Anton,Platt Robert W,Lee Hana,Bradley Marie CORCID

Abstract

ObjectivesTo examine valsartan, losartan and irbesartan usage and switching patterns in the USA, UK, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled.DesignRetrospective cohort study.SettingUSA, Canadian administrative healthcare data, Danish National Prescription Registry and UK primary care electronic health records.ParticipantsPatients aged 18 years and older between January 2014 and December 2020.InterventionValsartan, losartan and irbesartan.Main outcomeMonthly percentages of individual ARB episodes, new users and switches to another ARB, ACE inhibitors (ACEI) or calcium channel blockers containing products.ResultsWe identified 10.8, 3.2, 1.8 and 1.2 million ARB users in the USA, UK, Canada and Denmark, respectively. Overall proportions of valsartan, losartan and irbesartan use were 18.4%, 67.9% and 5.2% in the USA; 3.1%, 48.3% and 10.2% in the UK, 16.3%, 11.4% and 18.3% in Canada, 1%, 93.5% and 0.6% in Denmark. In July 2018, we observed an immediate steep decline in the proportion of valsartan use in the USA and Canada. A similar trend was observed in Denmark; however, the decline was only minimal. We observed no change in trends of ARB use in the UK. Accompanying the valsartan decline was an increase in switching to other ARBs in the USA, Canada and Denmark. There was a small increase in switching to ACEI relative to the valsartan-to-other-ARBs switch. We also observed increased switching from other affected ARBs, losartan and irbesartan, to other ARBs throughout 2019, in the USA and Canada, although the usage trends in the USA remained unchanged.ConclusionThe first recall notice for valsartan resulted in substantial decline in usage due to increased switching to other ARBs. Subsequent notices for losartan and irbesartan were also associated with increased switching around the time of the recall, however, overall usage trends remained unchanged.

Funder

US Food and Drug Administration

Canadian Institutes of Health Research

Publisher

BMJ

Subject

General Medicine

Reference14 articles.

1. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. 2018. Available: https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity [Accessed 26 May 2022].

2. EMA reviewing medicines containing valsartan from zhejiang huahai following detection of an impurity: some valsartan medicines being recalled across the EU. 2018. Available: https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some [Accessed 26 May 2022].

3. Several drugs containing valsartan being recalled due to contamination with a potential carcinogen. 2018. Available: https://recalls-rappels.canada.ca/en/alert-recall/several-drugs-containing-valsartan-being-recalled-due-contamination-potential [Accessed 26 May 2022].

4. Blood pressure and heart medication recalled from pharmacie. 2018. Available: https://www.gov.uk/government/news/blood-pressure-and-heart-medication-recalled-from-pharmacies [Accessed 26 May 2022].

5. International Agency for Research on Cancer . IARC monographs on the evaluation of carcinogenic risks to humans. overall evaluations of carcinogenicity: an updating of IARC monographs. 1987;1–42.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3